Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : n-Butylphthalide
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : Conjupro Biotherapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
NBP in Women With Metastatic Breast Cancer to Prevent Nab-paclitaxel Induced Toxic Neuropathy
Details : N-Butylphthalide is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 19, 2020
Lead Product(s) : n-Butylphthalide
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Conjupro Biotherapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
